Evogene Ltd.
EVGN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow EVGN
Evogene Ltd. (EVGN) Beneish M-score
Evogene Ltd.'s Beneish M-score for fiscal 2025 cannot be worked out: gross margin index cannot be worked out.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2024 | −2.43 | (1.05) |
| FY2023 | −1.38 | 1.69 |
| FY2022 | −3.07 | (0.78) |
| FY2021 | −2.29 | 0.23 |
| FY2020 | −2.53 | (347.47) |
| FY2019 | 344.94 | 347.70 |
| FY2018 | −2.76 | (0.07) |
| FY2017 | −2.69 | 0.69 |
| FY2016 | −3.38 | (1.47) |
| FY2015 | −1.91 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.86 | — | 0.79 | |
| Gross margin index | — | — | n/a | — |
| Asset quality index | 0.44 | — | 0.18 | |
| Sales growth index | 0.69 | — | 0.62 | |
| Depreciation index | 0.67 | — | 0.08 | |
| SG&A index | 0.93 | — | −0.16 | |
| Total accruals to total assets | 0.00 | — | 0.00 | |
| Leverage index | 0.37 | — | −0.12 | |
| Beneish M-score | n/a — gross margin index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| TCRT Alaunos Therapeutics, Inc. compare | −4.9× |
| ENVB Enveric Biosciences, Inc. compare | −4.7× |
| LEXX Lexaria Bioscience Corp. compare | −3.6× |
| TRAW Traws Pharma, Inc. compare | 2,517× |
| EVGN Evogene Ltd. | — |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI